{"nctId":"NCT00329238","briefTitle":"Secondary Prevention of Venous Thrombo Embolism (VTE).","startDateStruct":{"date":"2006-05"},"conditions":["Thromboembolism"],"count":2867,"armGroups":[{"label":"Dabigatran","type":"EXPERIMENTAL","interventionNames":["Drug: Dabigatran"]},{"label":"Warfarin (INR of 2.0-3.0)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Warfarin"]}],"interventions":[{"name":"Dabigatran","otherNames":[]},{"name":"Warfarin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\nInclusion\\_Criteria\n\n* Acute symptomatic deep vein thrombosis (DVT)\n* Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by objective testing\n\nExclusion criteria:\n\nExclusion\\_Criteria\n\n* Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more weeks during the 3-12 months of treatment for the prior VTE.\n* Patients who in the investigators judgement are perceived as having an excessive risk of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) \\> 2x ULN\n* Severe renal impairment (estimated creatinine clearance \\<= 30 ml/min)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Composite of Recurrent VTE or VTE Death at 36 Months","description":"Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1404","spread":null},{"groupId":"OG001","value":"1408","spread":null}]}]}]},{"type":"PRIMARY","title":"Composite of Recurrent VTE or VTE Death at 18 Months","description":"Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1408","spread":null},{"groupId":"OG001","value":"1409","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of Recurrent VTE or All Cause Death at 36 Months","description":"Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1388","spread":null},{"groupId":"OG001","value":"1390","spread":null}]}]}]},{"type":"SECONDARY","title":"Composite of Recurrent VTE or All Cause Death at 18 Months","description":"Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1394","spread":null},{"groupId":"OG001","value":"1394","spread":null}]}]}]},{"type":"SECONDARY","title":"Deep Vein Thrombosis (DVT) at 36 Months","description":"Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1413","spread":null},{"groupId":"OG001","value":"1413","spread":null}]}]}]},{"type":"SECONDARY","title":"DVT at 18 Months","description":"Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1415","spread":null},{"groupId":"OG001","value":"1414","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptomatic Pulmonary Embolism (PE) at 36 Months","description":"Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1420","spread":null},{"groupId":"OG001","value":"1421","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptomatic Pulmonary Embolism (PE) at 18 Months","description":"Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1422","spread":null},{"groupId":"OG001","value":"1421","spread":null}]}]}]},{"type":"SECONDARY","title":"Deaths Related to VTE at 36 Months","description":"Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1429","spread":null},{"groupId":"OG001","value":"1425","spread":null}]}]}]},{"type":"SECONDARY","title":"Deaths Related to VTE at 18 Months","description":"Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1429","spread":null},{"groupId":"OG001","value":"1425","spread":null}]}]}]},{"type":"SECONDARY","title":"Deaths of All Causes at 36 Months","description":"Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"19","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1413","spread":null},{"groupId":"OG001","value":"1407","spread":null}]}]}]},{"type":"SECONDARY","title":"Deaths of All Causes at 18 Months","description":"Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1415","spread":null},{"groupId":"OG001","value":"1410","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Bleeding Events","description":"MBE (major bleeding event) if it fulfilled at least one of the following criteria\n\n* Fatal bleeding\n* Symptomatic bleeding in a critical area or organ.\n* Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.\n\nMinor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs\n\nCRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria\n\n* Spontaneous skin haematoma ≥25 cm2\n* Spontaneous nose bleed \\>5 min duration\n* Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting \\>24 h\n* Spontaneous rectal bleeding\n* Gingival bleeding \\>5 min\n* Bleeding leading to hospitalisation or requiring surgical treatment\n* Bleeding leading to a transfusion of \\<2 units of whole blood or red cells\n* Any other bleeding event considered clinically relevant by the investigator","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"80","spread":null},{"groupId":"OG001","value":"145","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"277","spread":null},{"groupId":"OG001","value":"373","spread":null}]}]}]},{"type":"SECONDARY","title":"Laboratory Analysis","description":"Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"23","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Definite Acute Coronary Syndrome (ACS)","description":"All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":227,"n":1430},"commonTop":["Nasopharyngitis","Pain in extremity","Headache","Oedema peripheral","Influenza"]}}}